Effective Treatment of Advanced Breast Cancer with Vinorelbine, Mitomycin C, and G-CSF
Author Information
Author(s): GV Kornekl, K Haider, W Kwasny, M Hejnal, M Radererl, S Meghdadil, D Burger, B Schneeweiss, D Depisch, W Scheithauer
Primary Institution: Vienna University Medical School
Hypothesis
The study aims to evaluate the efficacy and tolerance of vinorelbine, mitomycin C, and G-CSF in patients with advanced breast cancer.
Conclusion
The combination of vinorelbine, mitomycin C, and G-CSF shows excellent anti-tumor activity in advanced breast cancer.
Supporting Evidence
- The overall response rate was 73%, with 22% achieving complete response.
- Among previously untreated patients, 28% achieved complete response.
- All nine patients with locally advanced disease were rated responsive.
Takeaway
This study tested a new treatment for advanced breast cancer and found that it worked really well for many patients.
Methodology
A phase II trial was conducted with 55 patients receiving vinorelbine, mitomycin C, and G-CSF, with evaluations of efficacy and toxicity.
Limitations
The study had a relatively small sample size and a short follow-up period.
Participant Demographics
Median age was 59 years, with 9 patients having locally advanced disease and 46 with distant metastases.
Statistical Information
Confidence Interval
95% confidence interval, 59-84%
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website